The Receivables Turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by average Accounts Receivable. An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. Vaccinex's Revenue for the
three
months ended in Mar. 2024 was $0.10 Mil. Vaccinex's average Accounts Receivable for the
three
months ended in Mar. 2024 was $1.87 Mil.
Hence, Vaccinex's Receivables Turnover for the
three
months ended in Mar. 2024 was 0.06.
Vaccinex Receivables Turnover Historical Data
The historical data trend for Vaccinex's Receivables Turnover can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Vaccinex's Receivables Turnover
For the Biotechnology subindustry, Vaccinex's Receivables Turnover, along with its competitors' market caps and Receivables Turnover data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Vaccinex's Receivables Turnover Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Vaccinex's Receivables Turnover distribution charts can be found below:
* The bar in red indicates where Vaccinex's Receivables Turnover falls into.
Vaccinex Receivables Turnover Calculation
Receivables Turnover measures the number of times a company collects its average accounts receivable balance.
Vaccinex's Receivables Turnover for the fiscal year that ended in Dec. 2023 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. This metric is commonly used to compare companies within the same industry to check whether they are on par with their competitors.
Vaccinex Receivables Turnover Related Terms
Thank you for viewing the detailed overview of Vaccinex's Receivables Turnover provided by GuruFocus.com. Please click on the following links to see related term pages.
Vaccinex Inc is pioneering a differentiated approach to treating cancer and slowly progressive neurodegenerative diseases through the inhibition of semaphorin 4D (SEMA4D). The company's lead drug candidate, pepinemab, blocks SEMA4D, a potent biological effector that it believes prevents immune infiltration into tumors and triggers inflammation in chronic diseases of the brain. Pepinemab is being evaluated in a Phase 1b/2 study in recurrent or metastatic head and neck cancer and in a Phase 1/2a study in Alzheimer's Disease, with ongoing exploration of potential Phase 3 development in Huntington's disease. The firm has also developed a proprietary drug discovery platform, ActivMAb. The firm generates revenue from collaborative research, license, development and commercialization agreements.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
VCNX has been successfully added to your 